This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Peter G. Shields, MD; Curtis C. Harris, MD

JAMA. 1991;266(5):681-687.

Abstract
Environmental, occupational, and recreational exposures to carcinogens contribute to cancer risk in humans. Cancer formation is a multistage process involving tumor initiation, promotion, conversion, and progression. Carcinogens can affect any of these stages through genetic and epigenetic mechanisms. The association of a suspected carcinogenic exposure and cancer risk can be studied in populations with classic epidemiologic techniques. However, these techniques are not applicable to the assessment of risk in individuals. Molecular epidemiology, in contrast, is a field that integrates molecular biology, in vitro and in vivo laboratory models, biochemistry, and epidemiology to infer individual cancer risk. Carcinogen-macromolecular adduct levels, and somatic cell mutations can be measured to determine the biologically effective dose of a carcinogen. Molecular epidemiology also explores host cancer susceptibilities, such as carcinogen metabolic activation, DNA repair, endogenous mutation rates, and inheritance of mutated tumor suppressor genes. Substantial interindividual variation for each of these biologic end points has been shown and, therefore, highlights the need for assessing cancer risk on an individual basis. Given the pace of the last decade, it is feasible that the next 10 years will allow molecular epidemiologists to develop a cancer-risk profile for an individual that includes assessment of a number of factors. This will help focus preventive strategies and strengthen quantitative risk assessments.

(JAMA. 1991;266:681-687)

Author Affiliations
From the Laboratory of Human Carcinogenesis, National Cancer Institute, National Institutes of Health, Bethesda, Md.

Footnotes
Reprint requests to Laboratory of Human Carcinogenesis, National Cancer Institute, National Institutes of Health, Bldg 37, Room 2C01, Bethesda, MD 20892 (Dr Harris).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Polymorphisms in Nucleotide Excision Repair Genes, Polycyclic Aromatic Hydrocarbon-DNA Adducts, and Breast Cancer Risk
Crew et al.
Cancer Epidemiol. Biomarkers Prev. 2007;16:2033-2041.
ABSTRACT | FULL TEXT  

Molecular cancer epidemiology: a tale of >3842 publications
Boffetta
Carcinogenesis 2007;28:1621-1621.
FULL TEXT  

Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer
Campa et al.
Carcinogenesis 2004;25:229-235.
ABSTRACT | FULL TEXT  

Polymorphisms in DNA Repair Genes and Associations with Cancer Risk
Goode et al.
Cancer Epidemiol. Biomarkers Prev. 2002;11:1513-1530.
ABSTRACT | FULL TEXT  

Sensitivity to DNA Damage Induced by Benzo(a)pyrene Diol Epoxide and Risk of Lung Cancer: A Case-Control Analysis
Li et al.
Cancer Res. 2001;61:1445-1450.
ABSTRACT | FULL TEXT  

Molecular Epidemiology: On the Path to Prevention?
Perera
JNCI J Natl Cancer Inst 2000;92:602-612.
ABSTRACT | FULL TEXT  

Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency
Linder et al.
Clin. Chem. 1997;43:254-266.
ABSTRACT | FULL TEXT  

Are Lean Smokers at Increased Risk of Lung Cancer? The Israel Civil Servant Cancer Study
Kark et al.
Arch Intern Med 1995;155:2409-2416.
ABSTRACT  

Mechanisms of Toxicity and Carcinogenesis
Trump
Toxicol Pathol 1995;23:775-827.
 

Platform Presentations
Toxicol Pathol 1993;21:611-623.
 

Poster Session
Toxicol Pathol 1993;21:623-646.
 

Head and Neck Cancer
Vokes et al.
NEJM 1993;328:184-194.
FULL TEXT  

Expanding the Boundaries of Medicine: Targeting a Common Enemy
Foege
JAMA 1991;266:702-702.
ABSTRACT